Treatment of the blastic phase of chronic myelogenous leukemia with high-dose cytosine arabinoside.
Sixteen patients with accelerated or blastic phase chronic myelogenous leukemia were treated with high-dose cytosine arabinoside given at 3 g/m2 every 12 h for two to eight doses per course. All patients had an immediate clearing of peripheral blood blast cells. Five patients achieved a complete response for 1-14 months, median 4.5 months. Toxicity was significant and predictable on the basis of dose given. We have identified both an effective and a toxic dosing schedule. The rapid response is dramatic but relatively short-lived, and suggests that additional agents in conjunction with reinfusion of autologous stem cells may offer these patients a greater chance of significant response.
Ernst
T J
TJ
Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115.
Rosenthal
D S
DS
Griffin
J D
JD
Canellos
G P
GP
D000328:Adult; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged
D003561:Cytarabine